RNA activation

RNA activation (RNAa) is a small RNA-guided and Argonaute (Ago)-dependent gene regulation phenomenon in which promoter-targeted short double-stranded RNAs (dsRNAs) induce target gene expression at the transcriptional/epigenetic level.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

RNA activation (RNAa) is a small RNA-guided and Argonaute (Ago)-dependent gene regulation phenomenon in which promoter-targeted short double-stranded RNAs (dsRNAs) induce target gene expression at the transcriptional/epigenetic level. RNAa was first reported in a 2006 PNAS paper by Li et al. who also coined the term "RNAa" as a contrast to RNA interference (RNAi) to describe such gene activation phenomenon. dsRNAs that trigger RNAa have been termed small activating RNA (saRNA).

Unlike RNAi, where small RNAs typically lead to gene silencing, RNAa demonstrates that small RNAs can also act as activators of gene expression.

Therapeutic Applications

RNAa offers promising therapeutic potential because of its ability to increase gene expression. This provides a different approach for treating diseases caused by gene underexpression or loss-of-function mutations. saRNAs for a number of genes have been tested in various cell and animal disease models for therapeutic efficacy.

Cancer: saRNAs have been used to reactivate tumor suppressor genes, inhibit cancer cell proliferation, and reduce tumor growth in animal models. Metabolic Disorders: saRNAs have been used to upregulate the expression of SIRT1, showing potential for reversing metabolic syndrome, and obesity.

Cardiovascular Disorders: saRNAs targeting VEGFA gene in the form of shRNA have been tested for the treatment of peripheral artery disease and myocardial infarction. and erectile dysfunction (ED). saRNA-mediated activation of βII spectrin alleviated ischemia/reperfusion (I/R)-induced cardiac contractile dysfunction. Genetic and Neuromuscular Disorders: The application of RNAa has been investigated for Myotonic Dystrophy type 1 (DM1), a dominant inherited neuromuscular disorder.

The core pathology of DM1 involves a toxic gain-of-function from expanded CUG repeats in the DMPK gene, which sequester Muscleblind-like (MBNL) proteins. This leads to a functional MBNL1 deficiency and a resulting disease-causing spliceopathy. In a study, saRNAs were designed to target the promoter of the MBNL1 gene.

The saRNAs were shown to increase MBNL1 transcription and protein levels (approximately 1.5–3 fold) in various cell models, including those derived from DM1 patients. Critically, this upregulation of endogenous MBNL1 was sufficient to correct or significantly mitigate key molecular defects, such as the mis-splicing of the insulin receptor (INSR), a primary biomarker for DM1.

The study provided a strong preclinical proof-of-concept for RNAa as a therapeutic strategy to address the root cause of DM1 and offered key engineering principles for future saRNA design. Neurodegenerative Disease: saRNAs targeting the BACE2 gene have been used to reduce Abeta production.

Other Therapeutic Applications: saRNAs have been tested in several other disease models, including acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) and proliferative vitreoretinopathy (PVR).

Clinical Progress

Several saRNA therapeutics have entered clinical trials: MTL-CEBPA: This saRNA targets the C/EBPα gene and is being evaluated for the treatment of advanced liver cancer. Early clinical trials showed that MTL-CEBPA was well-tolerated and demonstrated signs of clinical activity.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1375105848 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

4 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.